Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride

被引:17
作者
Hosokawa, Chisato [1 ]
Takeuchi, Satoshi [1 ]
Furue, Masutaka [1 ]
机构
[1] Kyushu Univ, Dept Dermatol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
atopic dermatitis; guideline; olopatadine hydrochloride; topical therapy; DAILY MANAGEMENT; INFLAMMATION; STEROIDS;
D O I
10.1111/j.1346-8138.2009.00621.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Atopic dermatitis (AD) is a common chronic or chronically relapsing, severely pruritic, eczematous skin disease. Recently, substance P (SP) has been demonstrated to be one of the important neuropeptides for mediating itch-scratch and stress-scratch cycles. In this study, we examined the severity scores, itch scores and plasma SP levels in 19 patients with AD treated with standard topical therapy with or without an oral antihistamine, olopatadine hydrochloride, for 4 weeks. The standard therapy decreased SCORAD scores, itch behavioral rating scores and plasma SP levels at post-treatment in the mass, but the topical therapy with olopatadine was more effective than the topical therapy alone, suggesting a potential additive effect.
引用
收藏
页码:185 / 190
页数:6
相关论文
共 30 条
[1]   From the brain-skin connection: The neuroendocrine-immune misalliance of stress and itch [J].
Arck, Petra ;
Paus, Ralf .
NEUROIMMUNOMODULATION, 2006, 13 (5-6) :347-356
[2]   Neurogenic inflammation in skin and airways [J].
Baluk, P .
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, 1997, :76-81
[3]   The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor [J].
Burbach, GJ ;
Kim, KH ;
Zivony, AS ;
Kim, A ;
Aranda, J ;
Wright, S ;
Naik, SM ;
Caughman, SW ;
Ansel, JC ;
Armstrong, CA .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (05) :1075-1082
[4]   Topical corticosteroid phobia in patients with atopic eczema [J].
Charman, CR ;
Morris, AD ;
Williams, HC .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (05) :931-936
[5]   International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies [J].
Ellis, C ;
Luger, T ;
Abeck, D ;
Allen, R ;
Graham-Brown, RAC ;
De Prost, Y ;
Eichenfield, LF ;
Ferrandiz, C ;
Giannetti, A ;
Hanifin, J ;
Koo, JYM ;
Leung, D ;
Lynde, C ;
Ring, J ;
Ruiz-Maldonado, R .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 :3-10
[6]   Development and evaluation of a chromatographic procedure for partial purification of substance P with quantitation by an enzyme immunoassay [J].
Fehder, WP ;
Ho, WZ ;
Campbell, DE ;
Tourtellotte, WW ;
Michaels, L ;
Cutilli, JR ;
Uvaydova, M ;
Douglas, SD .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1998, 5 (03) :303-307
[7]  
Fukiwake N, 2006, EUR J DERMATOL, V16, P416
[8]   Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis [J].
Furue, M ;
Terao, H ;
Moroi, Y ;
Koga, T ;
Kubota, Y ;
Nakayama, J ;
Furukawa, F ;
Tanaka, Y ;
Katayama, I ;
Kinukawa, N ;
Nose, Y ;
Urabe, K .
JOURNAL OF DERMATOLOGY, 2004, 31 (04) :277-283
[9]   Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis [J].
Furue, M ;
Terao, H ;
Rikihisa, W ;
Urabe, K ;
Kinukawa, N ;
Nose, Y ;
Koga, T .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (01) :128-133
[10]  
Furue M, 2008, Jpn J Dermatol, V118, P325